CPCI Stock Overview
Engages in the manufacturing and sale of pharmaceuticals, medical preparations, cosmetics, and materials in Egypt.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Kahira Pharmaceuticals & Chemical Industries Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م69.48 |
| 52 Week High | ج.م83.00 |
| 52 Week Low | ج.م37.15 |
| Beta | 0.041 |
| 11 Month Change | 5.27% |
| 3 Month Change | 8.78% |
| 1 Year Change | 62.98% |
| 33 Year Change | 83.28% |
| 5 Year Change | 134.60% |
| Change since IPO | 89.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPCI | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | -0.5% | 0.2% | 2.4% |
| 1Y | 63.0% | 27.3% | 62.0% |
Return vs Industry: CPCI exceeded the EG Pharmaceuticals industry which returned 27.3% over the past year.
Return vs Market: CPCI exceeded the EG Market which returned 62% over the past year.
Price Volatility
| CPCI volatility | |
|---|---|
| CPCI Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in EG Market | 9.0% |
| 10% least volatile stocks in EG Market | 3.3% |
Stable Share Price: CPCI has not had significant price volatility in the past 3 months.
Volatility Over Time: CPCI's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1962 | 1,930 | Yasser Farghali | www.kahirapharma.com |
Kahira Pharmaceuticals & Chemical Industries Company engages in the manufacturing and sale of pharmaceuticals, medical preparations, cosmetics, and materials in Egypt. The company is involved in the provision of chemicals, extracts, veterinary medicines, and pesticides; and packaging and distribution activities. It also exports its products to Iraq, Yemen, Sudan, Somalia, Jordan, Libya, Senegal, Zimbabwe, South Sudan, Mali, and Kenya.
Kahira Pharmaceuticals & Chemical Industries Company Fundamentals Summary
| CPCI fundamental statistics | |
|---|---|
| Market cap | ج.م1.04b |
| Earnings (TTM) | ج.م236.11m |
| Revenue (TTM) | ج.م1.38b |
4.4x
P/E Ratio0.7x
P/S RatioIs CPCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPCI income statement (TTM) | |
|---|---|
| Revenue | ج.م1.38b |
| Cost of Revenue | ج.م929.24m |
| Gross Profit | ج.م455.57m |
| Other Expenses | ج.م219.45m |
| Earnings | ج.م236.11m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 15.81 |
| Gross Margin | 32.90% |
| Net Profit Margin | 17.05% |
| Debt/Equity Ratio | 28.9% |
How did CPCI perform over the long term?
See historical performance and comparison